NEW YORK, NY / ACCESSWIRE / July 24, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) with a Price Target of $45.34.

The report is available here: AMBS Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Based in California, Amarantus BioScience Holdings (AMBSD) is a biotechnology company developing treatments and diagnostics neurology and orphan indications. As a biotechnology company, AMBS is developing treatments for wound healing, Parkinson's disease Levodopa-Induced Dyskinesia (PD-LID), Adult Attention Deficit Hyperactivity Disorder (ADHD), and Retinitis Pigmentosa, as well as developing better diagnostics to test for Alzheimer's disease and Multiple Sclerosis.

"AMBS has an impressive portfolio of product candidates across its diagnostic and therapeutic divisions. In particular, AMBS just recently announced that it has completed the acquisition of Cutanogen Corporation from Lonza Walkersville, Inc. a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute or ESS, a tissue-engineered skin replacement prepared from a patient's own skin cells. ESS has the potential to become a revolutionary treatment for severe burns and management believes that the path to approval for ESS could be rapid, potentially as quick as two years with market potential of $500 million," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $45.34 per share."

Additional highlights from the report are as follows:

Strong Portfolio of Lead Products in Therapeutic Division: Engineered Skin Substitute (ESS), Eltoprazine and MANF

AMBS's therapeutic division's lead product candidates are ESS, Eltoprazine and Mesencephalic-astrocyte-derived neurotrophic factor (MANF). ESS is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting. ESS is also being developed with support from the Armed Forces Institute for Regenerative Medicine (AFIRM). The AFIRM grant was initially worth $3mm with $0.75mm remaining and was awarded to support the IND and initial clinical studies. An IND with the US FDA is active, ESS has received orphan drug designation and a Phase 2 study is expected to open in 3Q15. Key catalysts in this program are around acceleration of the regulatory timeline as well as clinical data expected to come on a per patient basis given the special nature of the trial being initiated at a US military clinical site.

Eltoprazine is a small molecule 5HT1a/1b partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Adult ADHD, and Alzheimer's Aggression. Eltoprazine has been evaluated in over 600 human subjects to date, and has shown a strong and well established safety profile, as well as initial proof of concept data funded by the Michael J. Fox Foundation and published in the journal BRAIN. AMBS is expecting to have Phase 2b program clinical data in the first half of 2016 for Eltoprazine treatment in PD-LID.

MANF is believed to have broad potential because it is a naturally occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease. AMBS is the front-runner and primary holder of intellectual property around MANF, and is focusing on the development of MANF-based protein therapeutics. MANF has demonstrated efficacy as a disease-modifying treatment in various animal models, including retinitis pigmentosa, Parkinson's disease, cardiac ischemia and stroke. AMBS has also received European Union Orphan Drug Destination for MANF for the treatment of retinitis pigmentosa (RP). Amarantus expects to initiate human clinical studies in the second half of 2016 in RP.

Neuro-diagnostic division seeks to enhance the industry standard

AMBS's diagnostics division's lead developments are the MSPrecise(R) and the LymPro Test(R). MSPrecise(R) is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. MSPrecise(R) utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid.The Lymphocyte Proliferation Test, LymPro, is a diagnostic blood test for Alzheimer's disease that works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes following a mitogenic stimulation. If the CD69 is not up-regulated when measured, it means there is a dysfunctional cellular machinery division process, and Alzheimer's is more likely to be present. To help fuel the advancement of their Therapeutics pipeline, management has indicated they are evaluating strategic exit opportunities for their diagnostics division including potentially selling off the division, spinning off the division into its own company, or licensing the technologies to a third party.

PhenoGuard(TM) shows strong potential to further Drug Division

PhenoGuard(TM) is a proprietary discovery technology that played an essential role to developing MANF. Going forward, management believes that this drug discovery platform can be used to discover other, similar neurotrophic factors. The PhenoGuard(TM) technology currently consists of 88 cell lines, and management intends to expand the number of such cell lines through additional research.

Please review important disclosures on our website at www.seethruequity.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer's aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.

AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon

SeeThruEquity

info@seethruequity.com

SOURCE: SeeThruEquity

© 2024 Canjex Publishing Ltd. All rights reserved.